ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / NEPH
TELA (35) CVRX (31) BEAT (42) XTNT (65) ⌘ Pro Terminal →

Nephros Inc. (NEPH) — RQD Stock Rating Cockpit

$3.24 +2.21% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.25

Nephros Inc. (NEPH) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C- • HOLD / WATCH Cap $34.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NEPH Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NEPH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Nephros Inc. (NASDAQ: NEPH) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $3.24 (+2.21% 1D, market cap $34.5M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 15/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, NEPH ranks #175 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NEPH compare to TELA and CVRX in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), NEPH carries a Roarable C- (59/100 RQD), trailing P/E of 29.8x, gross margin of 61.9%, and ROIC of 18.9%. By comparison, TELA (TELA Bio Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $36.6M) and CVRX (CVRx Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $37.6M). Among the 5-stock peer group, NEPH leads on earnings multiple (29.8x) while NEPH leads on capital efficiency (18.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NEPH?
▼

Per NEPH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001196298), Nephros Inc. generated $18.8M in revenue (+32.7% YoY), $1.2M in net income, and $1.6M in free cash flow against $13.6M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (61.9% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $3.25 (+0.21%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 8.5% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY • 53.1% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C-
025507510059
2-of-3 Quant Analysts Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D+ · Rk C
Cash (16)Whales (3)SEC (15)Macro (10)CEO (15)
Each axis scored 0–20
12M PRICE TARGET CONE+0.3% Base Target
$7 Bull$3 Base$3 Bear
📬 FREE NEPH RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NEPH)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (59/100 Composite)
🔍 WHY NEPH SCORES 59/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (27% of score)

SEC XBRL FY 2025 (10-K): 8.5% FCF Margin ($1.6M FCF) & 61.9% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+15/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
67
Grade B-$3.59-1.9% Next Q
Q2 (-2Q)
64
Grade C+$3.52-0.3% Next Q
Q3 (-1Q)
62
Grade C+$3.51-7.7% Next Q
Current
59
Grade C-$3.24+0.2% Hist 90D α
Trajectory: B- (67) → C- (59)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the NEPH Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 59/100 (C-) score, NEPH faces multiple-compression risk if 29.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 59.4% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($3.86) or 200D SMA ($3.66) invalidates the momentum regime and cuts Target Base ($3.25) toward Bear Floor ($2.54).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NEPH• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NEPH Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 59%NO 41%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
3830 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
8 / 99-Pt Accounting
52-WEEK LASER RANGE15% OF RANGE
L: $3$3.24H: $6
1. Money & Cash Health● HEALTHY
Are profits real cash in the bank?

Real cash coming in backs up reported profits (61.9% gross margin and healthy balance-sheet cushion).

Factor Grade: B+RQD 16 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 18 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 25 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

2-of-3 Quant Analysts Bullish on NEPH

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BULLISH (80)

18.9% ROIC with 61.9% gross margin and 4.50% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (75)

Altman-Z 4.20 and Piotroski 8/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (47)

18/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like NEPH
  • ✓Strong cash generator (61.9% gross margin)—profits are backed by real money, not accounting tricks.
  • ✓Company leadership has skin in the game with net positive insider conviction.
  • ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
Bear Case: What Could Go Wrong
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (NEPH Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
NEPH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +5.54%📐 HORIZONTAL RANGE
2026-11-03O $3.27H $3.27L $3.17C $3.24VOL 12.4K
RES: $5.70SUP: $2.99SMA50: $3.86SMA200: $3.66
$5.01$4.44$3.87$3.29$2.72RES $5.70SUP $2.99$3.242026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NEPH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NEPH Butterfly Map → + Track NEPH →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
23.0%/yr Implied 5Y Growth

vs. +32.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NEPH today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NEPH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NEPH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NEPH)

Health Care Rank #175 of 1015 ⚔️ TELA vs NEPH Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NEPH vs. TELA, CVRX, BEAT, XTNT)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Nephros Inc. (NEPH) ranks #175 by composite RQD confidence (59/100, grade C-) and #783 by equity capitalization ($34.5M). Within this direct 5-issuer industry benchmark cohort, NEPH leads on earnings valuation at 29.8x trailing P/E, while NEPH leads on capital efficiency and profitability with 18.9% ROIC and 61.9% gross margin. XTNT currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with NEPH at 59/100 (C-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NEPH ACTIVE
Nephros Inc.
C- 59/100 29.8x 61.9% 18.9% +2.21% $34.5M Benchmark Subject
TELA
TELA Bio Inc.
D- 35/100 — 67.7% -35.0% -1.33% $36.6M /tela-vs-neph →
CVRX
CVRx Inc.
E 31/100 — 85.3% -35.0% -2.84% $37.6M /cvrx-vs-neph →
BEAT
Heartbeam Inc.
D- 42/100 — — -35.0% -25.64% $31.0M /beat-vs-neph →
XTNT
Xtant Medical Holdings Inc.
C 65/100 — 62.9% 12.8% -0.64% $39.3M /xtnt-vs-neph →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001196298 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nephros Inc. (NEPH) reported GAAP revenue of $18.8M (+32.7% vs. FY2024 revenue of $14.2M , and +32.0% cumulative change since FY2023) , GAAP net income of $1.2M, operating cash flow of $1.6M, and free cash flow of $1.6M (+392.5% YoY). On the balance sheet, NEPH closed FY2025 with $13.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $18.8M $1.2M $1.6M $1.6M $13.6M —
FY2024 (FY) 2024-12-31 $14.2M $74.0K -$492.0K -$547.0K $11.2M —
FY2023 (FY) 2023-12-31 $14.2M -$1.6M $827.0K $827.0K — —

3. NEPH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NEPH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Nephros Inc. (NASDAQ: NEPH) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $3.24 (+2.21% 1D, market cap $34.5M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 15/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, NEPH ranks #175 in composite RQD confidence.

How does NEPH compare to TELA and CVRX in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), NEPH carries a Roarable C- (59/100 RQD), trailing P/E of 29.8x, gross margin of 61.9%, and ROIC of 18.9%. By comparison, TELA (TELA Bio Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $36.6M) and CVRX (CVRx Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $37.6M). Among the 5-stock peer group, NEPH leads on earnings multiple (29.8x) while NEPH leads on capital efficiency (18.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NEPH?

Per NEPH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001196298), Nephros Inc. generated $18.8M in revenue (+32.7% YoY), $1.2M in net income, and $1.6M in free cash flow against $13.6M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (61.9% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NEPH trading relative to its 50-day, 200-day, and 52-week technical levels?

NEPH last traded at $3.24 (+2.21% on volume of 58,742 shares), positioning the stock -16.06% below its 50-day simple moving average ($3.86) and -11.48% below its 200-day simple moving average ($3.66). Across its 52-week range of $2.66 to $6.42, NEPH sits at the 15.4% percentile with a 14-day RSI of 38.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.83 to $3.65).

Direct Sub-Reports: NEPH RQD Cockpit NEPH 12M Forecast NEPH Earnings & Move NEPH Dividends & DRIP NEPH Insiders & 13F NEPH Whale Options NEPH Profit Sankey NEPH News & Why
ROARABLE RATING BRIEF • RQD 59/100 (C-) ✓ SEC XBRL & RQD VERIFIED

NEPH — Nephros Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Nephros Inc. (NEPH) earns a live Roarable RQD composite score of 59/100, corresponding to a C- letter grade (Roarable Hold) at a spot price of $3.24 (+2.21% 1D, market capitalization $34.5M).

  • Fundamental Cash Engine (16/20): Anchored by return on invested capital (ROIC) of 18.9%, gross margin of 61.9%, operating margin of 6.1%, and free cash flow yield of 4.50%.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (15/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (15/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 8/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

. Is a NASDAQ-listed issuer in the Health Care sector, Medical/Dental Instruments industry. Per the market data, gross margin is 61.9%, indicating meaningful pricing power or product mix advantage.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Nephros Inc. (NEPH) reported $18.8M in annual revenue (up from $14.2M in FY2024, +32.7% YoY) and $1.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($14.2M revenue, -$1.6M net income) through FY2025, NEPH scaled operating cash flow to $1.6M and free cash flow to $1.6M, backed by $13.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C- • RQD 59/100): Strong cash generator (61.9% gross margin)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 16/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $2.66 – $6.42 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh 29.8x trailing P/E and 26.3x EV/EBITDA against 6.1% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical/Dental Instruments (Health Care), NEPH carries a macro regime beta of 1.00 and gross margin of 61.9%.

  • Key Question #1: Can NEPH sustain or expand its 6.1% operating margin and 18.9% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $18.8M and free cash flow of $1.6M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is NEPH's 25.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NEPH Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Nephros Inc. (NEPH) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NEPH Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NEPH Bull vs. Bear Conversation Board — What's Your Call at $3.24?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NEPH 🐻 33% BEARISH CONVICTION
1. Pick Your Side on NEPH:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $3.80 (+19.9%)
📌 Pinned Debate

Revenue grew from $14.2M to $18.8M while ROIC of 18.9% and a Piotroski F-Score of 8/9 signal improving cash generation and balance shee

Long NEPH at $3.17 targeting $3.80. Revenue grew from $14.2M to $18.8M while ROIC of 18.9% and a Piotroski F-Score of 8/9 signal improving cash generation and balance sheet quality.. Institutional whale score is 3/20 and the risk/reward vs. the $2.66 52-week low is skewed heavily in favor of bulls.

VolSurface_Trader 🐂 BULL

Both sides have a point here — NEPH's 15/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $2.60 (-18.0%)
Spot @ $3.17

Valuation remains elevated at 29.8x TTM P/E and 26.3x EV/EBITDA against a 6.1% operating margin, with institutional whale flow scoring

Sitting on the sidelines or leaning short NEPH above $3.17. Valuation remains elevated at 29.8x TTM P/E and 26.3x EV/EBITDA against a 6.1% operating margin, with institutional whale flow scoring only 3/20.. Until Fundamental Cash Engine (16/20) and FCF yield (4.5%) inflect higher, upside is capped near $6.42.

LIVE TAPE